Table 3.
Effect of Selenomethionine on Food Intake and on Extra-Prostatic Tumor Development in 17β-Estradiol + Testosterone−Treated NBL Rats
| Group | 1 | 2 | 3 |
|---|---|---|---|
| Selenomethionine dose (as selenium-mg/kg diet) | 0 | 1.5 | 3 |
| Effective Number of Animals | 30 | 30 | 30 |
| Food Intake (g/week; mean ± SD −) 4 weeks | 132 ± 12.7 | 138 ± 6.1 | 143 ± 5.6* |
| 8 weeks | 140 ± 3.2 | 143 ± 10.0 | 144 ± 4.9 |
| 24 weeks | 132 ± 12.7 | 134 ± 8.0 | 137 ± 3.1 |
| Lesion Incidence | No. (%) of Rats with Lesion: | ||
| Pituitary tumors: | 30 (100) | 30 (100) | 30 (100) |
| Mammary Adenocarcinomas: | |||
| Total Mammary Cancer Incidence | 8 (27) | 3 (10) | 5 (17) |
| Tubulo-papillary carcinomas | 5 (17) | 2 (7) | 4 (14) |
| Compact/cribriform-comedo carcinomas | 3 (10) | 1 (3) | 1 (3) |
| Other tumors: | |||
| Thymic lymphoma | 3 (10) | 1 (3) | 3 (10) |
| Localized lymphoma of lymph nodes | 1 (3) | 1 (3) | 2 (7) |
| Skin: Squamous papilloma | 0 | 1 (3) | 0 |
| Adrenal pheochromocytoma | 2 (7) | 1 (3) | 1 (3) |
*
P < 0.01 for difference with control group (ANOVA with Dunnett’s multiple comparison test).